Oxaliplatin with high-dose leucovorin (LV) and 5-Fluorouracil (5FU) 48-hour infusion in pretreated metastatic colorectal cancer (FOLFOX6)

被引：0
|
作者：
Maindrault-Goebel, F
de Gramont, A
Louvet, C
Andre, T
Carola, E
Gilles-Amar, V
Izrael, V
Krulik, M
机构：
[1] Hop St Antoine, GERCOR, F-75012 Paris, France
[2] Hop Tenon, F-75020 Paris, France
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [21] Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with anthracycline and taxane refractory metastatic breast cancer (MBC).
    Kalbakis, K
    Kouroussis, C
    Kakolyris, S
    Mavroudis, D
    Souglakos, J
    Agelaki, S
    Vardakis, N
    Adamtziki, E
    Georgoulias, V
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 272 - 272
  • [22] Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
    Maindrault-Goebel, F
    Louvet, C
    André, T
    Carola, E
    Lotz, JP
    Molitor, JL
    Garcia, ML
    Gilles-Amar, V
    Izrael, V
    Krulik, M
    de Gramont, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) : 1338 - 1342
  • [23] Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV)
    Lin, YC
    Liu, HE
    Wang, CH
    Wang, HM
    Yang, TS
    Liau, CT
    Chen, JS
    ANTICANCER RESEARCH, 1999, 19 (6C) : 5615 - 5620
  • [24] Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer
    Chiara, S
    Nobile, MT
    Gozza, A
    Taveggia, P
    Heouaine, A
    Pastrone, I
    Percivale, PL
    Lionetto, R
    Sanguineti, O
    Rosso, R
    ANTICANCER RESEARCH, 2004, 24 (01) : 355 - 360
  • [25] Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer
    Bosset, JF
    DeGrammont, A
    Milan, C
    Rougier, P
    Bouche, O
    Etienne, PL
    Morvan, F
    Louvet, C
    Guillot, T
    Bedenne, L
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 702 - 702
  • [26] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [27] Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5FU
    Beretta, GD
    Cascinu, S
    Zaniboni, A
    Ratti, R
    Giordani, P
    Catalano, V
    Martignoni, G
    Barni, S
    Frontini, L
    Labianca, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S80 - S80
  • [28] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [29] Salvage chemotherapy with cyclophosphamide (C) and high-dose leucovorin (LV) and a 48-hour continuous infusion (CI) 5-fluorouracil (5-FU) in anthracycline-taxane refractory metastatic breast cancer (MBP). A phase II study.
    Kalbakis, K
    Kouroussis, C
    Souglakos, J
    Agelaki, S
    Mavroudis, D
    Reppa, D
    Bozionelou, V
    Kazakou, I
    Samonis, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 33 - 33
  • [30] 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer
    Falcone, A
    Allegrini, G
    Masi, G
    Lencioni, M
    Pfanner, E
    Brunetti, I
    Danesi, R
    Bocci, G
    Del Tacca, M
    Conte, P
    ONCOLOGY, 2001, 61 (01) : 28 - 35
12345